Esker SA
F:EKE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Esker SA
F:EKE
|
FR |
|
Macromill Inc
F:MA5
|
JP |
|
Radius Gold Inc
OTC:RDUFF
|
CA |
|
Ichiyoshi Securities Co Ltd
F:8KF
|
JP |
|
Calliditas Therapeutics AB
F:LC8
|
SE |
|
Koei Tecmo Holdings Co Ltd
OTC:TKHCF
|
JP |
|
P
|
PNM Resources Inc
F:98P
|
US |
|
A
|
Accsys Technologies PLC
F:1D8
|
UK |
|
E
|
Energeia AS
F:F62
|
NO |
|
Cizzle Biotechnology Holdings PLC
F:E7F0
|
UK |
|
GMO Payment Gateway Inc
F:3RH
|
JP |
|
China High Speed Transmission Equipment Group Co Ltd
F:BGR
|
HK |
|
A
|
ADENTRA Inc
F:UQ0
|
CA |
|
S2Medical AB (publ)
F:S21
|
SE |
|
S
|
Swiss Properties Invest A/S
F:SR1
|
DK |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is EKE's stock price target?
Not Available
EKE does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for Esker SA?
Projected CAGR
17%
Over the last 13 years, the compound annual growth rate for Revenue has been 14%. The projected CAGR for the next 4 years is 17%.
What is the Operating Income forecast for Esker SA?
Projected CAGR
32%
Over the last 13 years, the compound annual growth rate for Operating Income has been 19%. The projected CAGR for the next 3 years is 32%.